• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

J&J reports high foot-infection cure rate with experimental antibiotic

New Brunswick, N.J. - Johnson & Johnson says its experimental antibiotic ceftobiprole was found to cure 86 percent of patients with diabetic foot infections, Bloomberg.com reports.

New Brunswick, N.J. - Johnson & Johnson says its experimental antibiotic ceftobiprole was found to cure 86 percent of patients with diabetic foot infections, Bloomberg.com reports.

Johnson & Johnson, based here, reported the data at a recent medical meeting in San Diego, Calif. The company says the drug also cured methicillin-resistant Staphylococcus aureus (MRSA) infections.

Johnson & Johnson licenses the drug from Swiss co-developer Basilea Pharmaceutica AG.

Ceftobiprole’s 86 percent foot-infection cure rate compares with 81.8 percent reported for a combination therapy using vancomycin, an approved antibiotic, according to Johnson & Johnson.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.